Adial Pharmaceuticals (NASDAQ:ADIL) Issues Earnings Results

Adial Pharmaceuticals (NASDAQ:ADIL) announced its earnings results on Thursday. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01, FiscalAI reports.

Adial Pharmaceuticals Stock Performance

NASDAQ ADIL traded down $0.00 during trading hours on Friday, reaching $0.32. The company’s stock had a trading volume of 200,358 shares, compared to its average volume of 3,150,859. The company’s 50-day moving average is $0.36 and its two-hundred day moving average is $0.44. Adial Pharmaceuticals has a fifty-two week low of $0.22 and a fifty-two week high of $1.30. The stock has a market cap of $6.92 million, a PE ratio of -0.30 and a beta of 1.32.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ADIL. Maxim Group upgraded shares of Adial Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a research report on Tuesday, September 30th. Wall Street Zen upgraded shares of Adial Pharmaceuticals to a “sell” rating in a research report on Saturday, July 26th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adial Pharmaceuticals in a report on Wednesday, October 8th. Finally, Zacks Research downgraded Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 20th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $1.50.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.